Latest News | Zydus Inks Pact to Acquire Stake in US Firm to Enter Contract Manufacturing Space

New Delhi, Jun 3 (PTI) Zydus Lifesciences on Tuesday said it has inked a pact to acquire 5.9 per cent stake in US-based Agenus Inc for around USD 16 million, marking its entry into the global biologics contract development and manufacturing organisation (CDMO) sector.

Zynext Ventures USA LLC, a wholly-owned subsidiary of the company, has inked a securities purchase agreement with Agenus to acquire 21,33,333 shares at a purchase price of USD 7.50 per share aggregating to around USD 16 million, the drug firm said in a regulatory filing.

Also Read | Mumbai Water Taxi Service: Maharashtra Govt To Soon Roll Out Water Taxis From Gateway of India to Navi Mumbai Airport.

The transaction will allow the Gujarat-based Zydus to access Agenus's biologics manufacturing facilities in California, US.

The acquisition positions Zydus at the forefront of the fast-growing global biologics CDMO market, establishing a robust presence in the world's leading biotech innovation hub, it added.

Also Read | Bodoland Lottery Result Today, June 03, 2025: Assam State Lottery Sambad Tuesday Lucky Draw Results Declared, Check Winners List With Ticket Numbers.

With this strategic move, Zydus gains immediate access to advanced biologics development and manufacturing capabilities, further enabling partnerships with innovative biotechnology companies and enhancing its global footprint in high-growth markets, it said.

"The acquisition will give Zydus a strategic foothold in the US for biologics manufacturing in the global hub for biotech innovation, California," Zydus Lifesciences MD Sharvil Patel said.

It will enhance the company's ability to partner with innovation-centric entities, advancing new products and prioritizing patient-centric solutions, he added.

Besides, Zydus Lifesciences said it has entered into a definitive agreement with Agenus Inc to secure exclusive commercial rights for India and Sri Lanka for their investigational immuno-oncology therapies -- Botensilimab (BOT) and Balstilimab (BAL).

These next-generation therapies are designed to address high-unmet needs across multiple cancer types and have demonstrated significant clinical activity in advanced trials involving over 1,200 patients, it added.

Zydus shares on Tuesday ended 0.26 per cent down at Rs 926.50 apiece on BSE.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)